Malmstroma PU, Sylvester RJ, Crawford DE, et al: An individual patient data meta-anaiysis, of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56: 247-256, 2009
Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, Ti and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124-1129, 2000
Hinotsu S, Naito S, Ozono S, et al: Prophylactic effect of 1.5 year maintenance PMCJ-9 (BCG Connaught strain) therapy for nonmuscle invasive urothelial carcinoma of the bladder (NMIBC). Results of interim analysis of prospective randomized phase III trial in Japan.2009 Genitourinary Cancers Symposium. Abstract No.251
Dalbagni G, Russo P, Bochner B, et al: Phase II trial of intravesical gemcitabine in bacilli CalmetteGuerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24: 2729-2734, 2006